Eris Lifesciences expects 150-200 basis point gross margin expansion in second half as biologics scale up

Eris Lifesciences expects profitability to improve as biologics production ramps up and acquired businesses continue to scale. The company also expects India's semaglutide market to grow significantly over the next year while planning faster debt reduction as its capex cycle slows.